Skip to main content

Apimeds Pharmaceuticals US, Inc.

APUS
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001894525

No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.

Holders of 5% or more of APUS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Apimeds Pharmaceuticals US, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of APUS
HolderLatest formStakeChangeFirst filedLatest filingFiling
Inscobee Inc.13D/A34.30%4.32M shares0.00 ppfrom 34.30%May 19, 20255 filingsMay 7, 2026SEC
Ayrton Capital LLC13G9.99%1.40M sharesNewFeb 11, 20261 filingFeb 11, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Apimeds Pharmaceuticals US, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on APUS
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 7, 20269:11 AM ETInscobee Inc.and 1 other13D/A34.30%4.32M shares0.00 ppfrom 34.30%May 7, 2026SEC
Mar 30, 20268:20 AM ETInscobee Inc.and 1 other13D/A34.30%4.32M shares0.00 ppfrom 34.30%Mar 25, 2026SEC
Mar 20, 20266:21 PM ETInscobee Inc.and 1 other13D/A34.30%4.32M shares0.00 ppfrom 34.30%Mar 20, 2026SEC
Feb 11, 20269:51 AM ETAyrton Capital LLCand 2 others13G9.99%1.40M sharesNewDec 31, 2025SEC
Jan 26, 20266:03 AM ETInscobee Inc.and 1 other13D/A34.30%4.32M shares−3.60 ppfrom 37.90%Dec 1, 2025SEC
May 19, 20259:29 PM ETInscobee Inc.and 1 other13D37.90%4.39M sharesNewMay 12, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Apimeds Pharmaceuticals US, Inc. shares.

No Form 144 notices for Apimeds Pharmaceuticals US, Inc. are on file.